エピソード

  • ABBV Today - Aug 13: Solid Day on the Street

    ABBV Today - Aug 13: Solid Day on the Street
    2026/08/13
    Hey there! It's Joey, your friendly investor buddy, breaking down what went down with AbbVie today. So, ABBV had a solid day, up about 1.6%. Not too shabby!

    Now, let’s talk about what happened. The stock was pretty active, trading around 1 million shares today, which is right on par with its usual hustle. It opened strong and kept the momentum going, hitting a high of about 255. That kind of action gets people interested, you know?

    So, why the good vibes? Well, there’s been some chatter around AbbVie’s pipeline and its recent quarterly results. They dropped some strong numbers for Q2 and even raised guidance for 2026, which definitely turned some heads. Investors love to see that kind of optimism! Plus, Wolfe Research gave a nod to AbbVie, saying it’s looking good in the grand scheme of things compared to its peers. With new approvals coming down the line, folks are feeling pretty bullish about their future.

    Also, there’s been some buzz comparing AbbVie to companies like Johnson & Johnson and Pfizer. Some analysts are saying AbbVie’s dividend yield is looking pretty appealing, especially when you stack it up against the competition. It’s always nice to know you’re holding onto something that might pay off down the road.

    One thing to keep an eye on is how these approvals and pipeline developments play out. If they keep landing those approvals, it could really shift the narrative around AbbVie, making it even more attractive for investors.

    So, to wrap it up, AbbVie had a nice little bump today, and the news around its earnings and future outlook is definitely giving it some steam. Just remember, this info is for fun and to keep you in the loop, not financial advice. Catch you later!
    続きを読む 一部表示
    2 分
  • ABBV Today - Aug 12: Downgrade Hits AbbVie

    ABBV Today - Aug 12: Downgrade Hits AbbVie
    2026/08/12
    Hey there! It’s Joey, your friendly stock enthusiast. I’ve been investing for years, and today, I’m breaking down AbbVie, or ABBV, and it was a red day—down just a smidge, like 0.1%. Not a huge drop, but still a bummer.

    So, here’s the scoop. AbbVie kind of coasted today, barely moving at all. It’s like when you’re just chilling on the couch, not really doing much. The stock was hovering around $249.83, so not a wild ride. But what’s interesting is that BTIG decided to downgrade Apogee Therapeutics, which is tied to AbbVie’s recent deal. That probably made some folks a bit uneasy, you know?

    Now, onto the why. The market’s always got its ears perked up, and when news like a downgrade drops, people start hitting the sell button fast. It’s a chain reaction—when one piece of news hits, it can shake things up for other related stocks. Plus, there’s been chatter comparing AbbVie with CVS Health and Pfizer lately. Everyone’s trying to figure out who’s the better buy, and that’s always gonna cause some waves. It’s like a high school popularity contest, but for stocks.

    Oh, and here’s a little tidbit for you—AbbVie is waiting on the FDA to review a new use for BOTOX. That could be a game-changer if it goes through, so keep an eye on that.

    Alright, that’s a wrap for today! Just remember, this is all for fun and info, not financial advice. Stay curious, and I’ll catch you later!
    続きを読む 一部表示
    1 分
  • ABBV Today - Aug 11: $8 Billion Debt Deal

    ABBV Today - Aug 11: $8 Billion Debt Deal
    2026/08/11
    Hey there! It’s Joey here, your friendly neighborhood investor. I’ve been in the game for a while, and today, we’re talking about AbbVie. So, how did it do? Well, it was a pretty chill day, barely moved, closing up just a smidge at 0.26%.

    So, what’s the scoop? AbbVie just took on a whopping $8 billion in debt for its Apogee deal. Yeah, that one stung a bit for some folks. When you hear “debt,” it usually raises eyebrows, especially for dividend investors. People were wondering if this move might hurt their precious payouts down the line.

    Now, here’s the thing. Some analysts are a bit worried about AbbVie’s earnings potential. Like, Erste Group Bank just lowered its EPS estimates for FY2027. That’s not exactly a warm hug for investors looking for growth. And to add to the mix, BNP Paribas adjusted their price target on AbbVie to $247, which is a bit of a bump up from where it was, but they’re still neutral on the stock. So, it’s like, they’re saying, “We see potential, but we’re not super excited about it.”

    But don’t let that totally bring you down. AbbVie did post some strong Q2 earnings recently, which had some investors feeling a little more optimistic. It’s like they’re trying to balance the good with the not-so-good.

    One thing worth knowing about is that this big debt deal might signal AbbVie’s plans to invest heavily in its pipeline. They’re all about growth, and sometimes you gotta take risks to get there. So, keep an eye on how they manage this debt and what it means for their future projects.

    Alright, that’s the lowdown on AbbVie today! Remember, this is just for fun and info—no financial advice here. Catch you later!
    続きを読む 一部表示
    2 分
  • ABBV Today - Aug 10: Mixed Reactions Post Earnings

    ABBV Today - Aug 10: Mixed Reactions Post Earnings
    2026/08/10
    Hey there! It’s Joey, your friendly investor buddy, here to break down what went down with AbbVie today. So, AbbVie had a bit of a red day, slipping just a smidge by about a quarter percent. Not a huge drop, but still, nobody likes to see their stocks in the red, right?

    So, here’s the scoop. AbbVie posted some strong Q2 earnings recently, which usually gets people hyped. But today, it felt like the excitement was kinda muted. Some folks were probably expecting a bigger reaction, but it just didn’t happen. Volume was steady, so it wasn’t like there was panic selling or anything—just a slow bleed, you know?

    Now, let’s talk about why this happened. A couple of articles I checked out pointed to mixed feelings about AbbVie’s future after those earnings. They did show solid numbers, but there’s chatter about the Apogee financing deal and how that’s playing into the stock’s vibes. Apogee reported a pretty hefty loss for Q2, but the potential of their atopic dermatitis drug showing promising results got some attention. It’s like, yeah, there’s good stuff happening, but people are still a bit cautious, maybe waiting to see how it all unfolds.

    And hey, something to keep in mind: AbbVie’s got that Apogee deal hanging over them, and it’s a big one. Analysts are watching closely to see how that plays out, especially since it involves financing and could signal a lot about AbbVie’s strategy moving forward.

    So, to wrap it up, AbbVie had a little hiccup today, but it’s not all doom and gloom. They’ve got some strong earnings backing them up, and the Apogee deal might just be the wild card in the deck. Just remember, this is all for fun and info—not financial advice! Catch you later!
    続きを読む 一部表示
    2 分
  • ABBV Today - Aug 09: Mixed signals on revenue

    ABBV Today - Aug 09: Mixed signals on revenue
    2026/08/09
    Hey there! It’s Joey here, your friendly longtime investor, breaking down today’s stock action. We’re talking about AbbVie, and it was a pretty chill day — the stock was up just a smidge, about 0.9%.

    So, here’s the scoop. AbbVie started the day with some good vibes but ended up kinda flat. It bounced around a bit but didn’t really make any big moves. There were a few things stirring the pot, but nothing that really sent it soaring or crashing.

    Now, let’s get into the why of it all. One article pointed out that AbbVie’s Rinvoq is expanding its reach in Europe, which is generally a good look for the company. But then there was a buzzkill — they raised their 2026 revenue outlook and issued new debt, which sent the stock down about 5.3% earlier this week. Yeah, that one stung. Investors are always a bit jittery about debt, and it seems like that’s what happened here. So, mixed signals all around.

    Also, there’s chatter comparing AbbVie to Abbott Laboratories, which is another healthcare stock. Some folks are weighing which one’s the better buy in 2026. That’s interesting, but honestly, it's just more noise in the background right now.

    Oh, and something worth keeping an eye on: AbbVie’s dividend game is still strong, and they’ve been mentioned as one of the top picks for dividends right now. That’s a nice little perk if you’re holding onto the stock.

    So, to wrap it up, AbbVie had a day where it kinda just waddled along, with some good news about Rinvoq but also some worries over debt. Just another day in the stock market, right? Remember, this is just for your info and entertainment, not financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • ABBV Today - Aug 08: Stock May Be Undervalued

    ABBV Today - Aug 08: Stock May Be Undervalued
    2026/08/08
    Hey there! It’s Joey, your friendly investor buddy, here to break down the day for AbbVie. So, ABBV had a pretty chill day, barely moving, up just a bit—like 0.89%.

    What went down? Well, it kinda stayed flat, just hovering around that $246 mark. Nothing too wild, right? But here's the scoop. There’s chatter that AbbVie might be 45% below its fair value because of its Rinvoq expansion in Europe. Sounds promising, but it didn’t really light a fire under the stock today.

    Now, the reason for the slight dip earlier this week was a bit of a head-scratcher. They raised their 2026 revenue outlook, which usually gets people excited, but then they also announced some new debt. Talk about mixed signals, right? Investors hit the sell button a bit after that news dropped, and that stung.

    Oh, and there’s some buzz about AbbVie in comparison to Abbott Laboratories. They’re being compared on who’s the better healthcare stock right now. It’s a bit of a showdown! And let’s not forget, there was a recent purchase of over 5,200 shares by MRA Advisory Group. Always interesting to see who’s buying in.

    Looking ahead, keep an eye on Rinvoq’s rollout in Europe. That could be a game changer if it picks up traction.

    So, that’s the lowdown on AbbVie today! Just remember, I’m here to keep you in the loop, not to give you any financial advice. Stay savvy out there! Catch you later!
    続きを読む 一部表示
    1 分
  • ABBV Today - Aug 07: Analysts Question Earnings Call

    ABBV Today - Aug 07: Analysts Question Earnings Call
    2026/08/07
    Hey there! It’s Joey, your friendly stock enthusiast, here to break down the day for AbbVie, ticker symbol ABBV. Today was a bit of a mixed bag, but overall, it was a red day, with the stock dipping just a smidge, down about half a percent.

    So, what went down? Well, AbbVie started the day strong but then kind of faded, ending the day on a low note. It felt like a slow bleed as folks were reacting to some of the chatter coming out of their recent earnings call. You know how it goes—when the vibes are off, people tend to hit that sell button fast.

    Now, let’s get into why this happened. Analysts had some interesting questions during AbbVie’s Q2 earnings call, and while the company reported solid numbers, there’s always that nagging uncertainty. Some investors were left scratching their heads about future growth and how AbbVie plans to tackle the competitive landscape. Plus, there was chatter about their recent $9.9 billion senior notes offering to fund an acquisition. That’s a hefty price tag, and it made some people a bit jittery. They want to know if that’s gonna pay off in the long run or if it’s just a gamble.

    Oh, and here’s something worth knowing: AbbVie’s got a big focus on its pipeline, especially with their new treatments coming down the line. So while today was a bit of a stumble, there’s still potential for some exciting stuff ahead.

    Alright, that’s the scoop for today! Remember, I’m just here sharing the info and having a good time chatting about stocks, so don’t take this as financial advice. Catch you later!
    続きを読む 一部表示
    1 分
  • ABBV Today - Aug 06: Dividend News and Predictions

    ABBV Today - Aug 06: Dividend News and Predictions
    2026/08/06
    Hey there! It’s Joey here, your friendly neighborhood investor, and I’m breaking down the day for you. Today we’re talking about AbbVie, and it had a bit of a rough day, down about 1.6%.

    So, what happened? Well, the stock got smoked today, losing some ground. It’s kinda wild because AbbVie usually has a solid reputation, but today it just didn’t have that spark.

    Now, let’s get into the why. There’s chatter in the air about AbbVie’s dividend game, and let me tell you, they’ve been raising it consistently no matter what’s happening in the market. Wall Street seems to think that’s a good sign, and some folks are still calling it a buy. But then there’s also the buzz around their Q2 earnings, which raised some eyebrows. They’re dealing with the cost of the Apogee deal, and investors are kinda scratching their heads over how that’s going to play out. It’s a mixed bag right now, honestly.

    On the horizon, AbbVie’s future predictions are getting a lot of attention. Some analysts are throwing out price targets for the end of the year, which is always an interesting game to watch.

    So, to wrap it up, AbbVie had a tough day, but the dividend news keeps some hope alive. Just remember, this is all for fun and info, not financial advice! Catch you later!
    続きを読む 一部表示
    1 分